Medpace Holdings Inc vs Ferrari NV — how do they compare? Medpace Holdings Inc trades at $530.58 (market cap $15.08B), while Ferrari NV trades at $370.11 (market cap $65.48B). The key difference: Ferrari NV is far larger — about 4.3× Medpace Holdings Inc's market cap, and Ferrari NV pays a 1.14% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | RACE | |
|---|---|---|
Market Cap | $15.08B | $65.48B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $517.65 |
52-Week Low | $308.88 | $314.63 |
Enterprise Value | $14.55B | $66.69B |
Dividend Yield | — | 1.14% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Ferrari (RACE) trades at $371.52, down 1.41% on the day, with a bullish technical signal from moving averages. The company exhibits strong fundamentals, including a 22.19% net income margin and consistent earnings beats, with Q2 2026 results due July 30, 2026. Recent news highlights institutional buying, a share buyback program, and the debut of its first electric vehicle, though the Luce model received mixed initial reception.
The outlook remains positive given analyst consensus, with a $467.50 price target implying significant upside. Key risks include execution on the EV transition and high valuation multiples. The stock presents a growth opportunity driven by brand strength and pricing power, but investors should weigh near-term volatility around earnings.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →